Account wins from the 02/17/06 News Brief

Share this article:
PDI announced a three-year agreement with Ascend Therapeutics to promote their estrogen replacement therapy product, EstroGel, to the obstetrician/gynecologist market. PDI will initially provide a specialty sales team of 50 field representatives, with the expectation the field force will grow over time. The program is due to run through Jan. 31, 2008, with an automatic extension through Jan. 31, 2009, if certain conditions are met.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions